1.Predictors of Choledocholithiasis in Cholecystectomy Patients and Their Cutoff Values and Prediction Model in Korea in Comparison with the 2019 ASGE Guidelines
Jung Hun WOO ; Hwanhyi CHO ; Kihyun RYU ; Young Woo CHOI ; Sanghyuk LEE ; Tae Hee LEE ; Dae Sung KIM ; In Seok CHOI ; Ju Ik MOON ; Seung Jae LEE
Gut and Liver 2024;18(6):1060-1068
Background/Aims:
In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) established clinical predictors for choledocholithiasis. Our study was designed to evaluate these predictors within the Korean clinical context, establish cutoff values, and develop a predictive model.
Methods:
This retrospective study analyzed patients who underwent laparoscopic cholecystectomy. The relationships between choledocholithiasis and predictors including age, blood tests, and imaging findings were assessed through univariate and multivariate logistic regression analyses. We established Korean cutoff values for these predictors and developed a scoring system for choledocholithiasis using a multivariate logistic regression. The performance of this scoring system was then compared with that of the 2019 ASGE guidelines through a receiver operating characteristic curve.
Results:
We established Korean cutoff values for age (>70 years), alanine aminotransferase (>26.5 U/L), aspartate aminotransferase (>28.5 U/L), gamma-glutamyl transferase (GGT; >82.5 U/L), alkaline phosphatase (ALP; >77.5 U/L), and total bilirubin (>0.95 mg/dL). In the multivariate analysis, only age >70 years, GGT >77.5 U/L, ALP >77.5 U/L, and common bile duct dilatation remained significant. We then developed a new Korean risk stratification model from the multivariate analysis, with an area under the curve of 0.777 (95% confidence interval, 0.75 to 0.81).Our model was stratified into the low-risk, intermediate-risk, and high-risk groups with the scores being <1.0, 1.0–5.5, and >5.5, respectively.
Conclusions
Predictors of choledocholithiasis in cholecystectomy patients and their cutoff values in Korean should be adjusted and further studies are needed to develop appropriate guidelines.
2.Predictors of Choledocholithiasis in Cholecystectomy Patients and Their Cutoff Values and Prediction Model in Korea in Comparison with the 2019 ASGE Guidelines
Jung Hun WOO ; Hwanhyi CHO ; Kihyun RYU ; Young Woo CHOI ; Sanghyuk LEE ; Tae Hee LEE ; Dae Sung KIM ; In Seok CHOI ; Ju Ik MOON ; Seung Jae LEE
Gut and Liver 2024;18(6):1060-1068
Background/Aims:
In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) established clinical predictors for choledocholithiasis. Our study was designed to evaluate these predictors within the Korean clinical context, establish cutoff values, and develop a predictive model.
Methods:
This retrospective study analyzed patients who underwent laparoscopic cholecystectomy. The relationships between choledocholithiasis and predictors including age, blood tests, and imaging findings were assessed through univariate and multivariate logistic regression analyses. We established Korean cutoff values for these predictors and developed a scoring system for choledocholithiasis using a multivariate logistic regression. The performance of this scoring system was then compared with that of the 2019 ASGE guidelines through a receiver operating characteristic curve.
Results:
We established Korean cutoff values for age (>70 years), alanine aminotransferase (>26.5 U/L), aspartate aminotransferase (>28.5 U/L), gamma-glutamyl transferase (GGT; >82.5 U/L), alkaline phosphatase (ALP; >77.5 U/L), and total bilirubin (>0.95 mg/dL). In the multivariate analysis, only age >70 years, GGT >77.5 U/L, ALP >77.5 U/L, and common bile duct dilatation remained significant. We then developed a new Korean risk stratification model from the multivariate analysis, with an area under the curve of 0.777 (95% confidence interval, 0.75 to 0.81).Our model was stratified into the low-risk, intermediate-risk, and high-risk groups with the scores being <1.0, 1.0–5.5, and >5.5, respectively.
Conclusions
Predictors of choledocholithiasis in cholecystectomy patients and their cutoff values in Korean should be adjusted and further studies are needed to develop appropriate guidelines.
3.Predictors of Choledocholithiasis in Cholecystectomy Patients and Their Cutoff Values and Prediction Model in Korea in Comparison with the 2019 ASGE Guidelines
Jung Hun WOO ; Hwanhyi CHO ; Kihyun RYU ; Young Woo CHOI ; Sanghyuk LEE ; Tae Hee LEE ; Dae Sung KIM ; In Seok CHOI ; Ju Ik MOON ; Seung Jae LEE
Gut and Liver 2024;18(6):1060-1068
Background/Aims:
In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) established clinical predictors for choledocholithiasis. Our study was designed to evaluate these predictors within the Korean clinical context, establish cutoff values, and develop a predictive model.
Methods:
This retrospective study analyzed patients who underwent laparoscopic cholecystectomy. The relationships between choledocholithiasis and predictors including age, blood tests, and imaging findings were assessed through univariate and multivariate logistic regression analyses. We established Korean cutoff values for these predictors and developed a scoring system for choledocholithiasis using a multivariate logistic regression. The performance of this scoring system was then compared with that of the 2019 ASGE guidelines through a receiver operating characteristic curve.
Results:
We established Korean cutoff values for age (>70 years), alanine aminotransferase (>26.5 U/L), aspartate aminotransferase (>28.5 U/L), gamma-glutamyl transferase (GGT; >82.5 U/L), alkaline phosphatase (ALP; >77.5 U/L), and total bilirubin (>0.95 mg/dL). In the multivariate analysis, only age >70 years, GGT >77.5 U/L, ALP >77.5 U/L, and common bile duct dilatation remained significant. We then developed a new Korean risk stratification model from the multivariate analysis, with an area under the curve of 0.777 (95% confidence interval, 0.75 to 0.81).Our model was stratified into the low-risk, intermediate-risk, and high-risk groups with the scores being <1.0, 1.0–5.5, and >5.5, respectively.
Conclusions
Predictors of choledocholithiasis in cholecystectomy patients and their cutoff values in Korean should be adjusted and further studies are needed to develop appropriate guidelines.
4.Predictors of Choledocholithiasis in Cholecystectomy Patients and Their Cutoff Values and Prediction Model in Korea in Comparison with the 2019 ASGE Guidelines
Jung Hun WOO ; Hwanhyi CHO ; Kihyun RYU ; Young Woo CHOI ; Sanghyuk LEE ; Tae Hee LEE ; Dae Sung KIM ; In Seok CHOI ; Ju Ik MOON ; Seung Jae LEE
Gut and Liver 2024;18(6):1060-1068
Background/Aims:
In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) established clinical predictors for choledocholithiasis. Our study was designed to evaluate these predictors within the Korean clinical context, establish cutoff values, and develop a predictive model.
Methods:
This retrospective study analyzed patients who underwent laparoscopic cholecystectomy. The relationships between choledocholithiasis and predictors including age, blood tests, and imaging findings were assessed through univariate and multivariate logistic regression analyses. We established Korean cutoff values for these predictors and developed a scoring system for choledocholithiasis using a multivariate logistic regression. The performance of this scoring system was then compared with that of the 2019 ASGE guidelines through a receiver operating characteristic curve.
Results:
We established Korean cutoff values for age (>70 years), alanine aminotransferase (>26.5 U/L), aspartate aminotransferase (>28.5 U/L), gamma-glutamyl transferase (GGT; >82.5 U/L), alkaline phosphatase (ALP; >77.5 U/L), and total bilirubin (>0.95 mg/dL). In the multivariate analysis, only age >70 years, GGT >77.5 U/L, ALP >77.5 U/L, and common bile duct dilatation remained significant. We then developed a new Korean risk stratification model from the multivariate analysis, with an area under the curve of 0.777 (95% confidence interval, 0.75 to 0.81).Our model was stratified into the low-risk, intermediate-risk, and high-risk groups with the scores being <1.0, 1.0–5.5, and >5.5, respectively.
Conclusions
Predictors of choledocholithiasis in cholecystectomy patients and their cutoff values in Korean should be adjusted and further studies are needed to develop appropriate guidelines.
5.Factors Affecting Adherence to National Colorectal Cancer Screening:A 12-Year Longitudinal Study Using Multi-Institutional Pooled Data in Korea
Dae Sung KIM ; Jeeyoung HONG ; Kihyun RYU ; Sang Hyuk LEE ; Hwanhyi CHO ; Jehyeong YU ; Jieun LEE ; Jong-Yeup KIM
Journal of Korean Medical Science 2024;39(4):e36-
Background:
Consistent uptake of colorectal cancer (CRC) screening is important to reduce the incidence and mortality from advanced-stage CRC and increase the survival rate of the patients. We conducted a longitudinal study to determine the factors affecting CRC screening compliance in Korean adults using individual-level linked data from the Korean National Health and Nutrition Examination Survey, Korean National Health Insurance Service, and Korean Health Insurance Review and Assessment Service.
Methods:
We selected 3,464 adults aged 50–79 years as the study population and followed them for 12 years (January 2007–December 2018). The outcome variable was the level of adherence to CRC screening, categorized as nonadherent, intermittently adherent, and consistently adherent. An ordinal logistic regression model was designed to determine the socioeconomic factors, family history of CRC, and medical conditions that could facilitate the consistent uptake of CRC screening.
Results:
The results showed a significant and positive association between consistent uptake of CRC screening and the 100–150% income category (odds ratio [OR], 1.710; 95% confidence interval [CI], 1.401–2.088); clerical, sales and service job category (OR, 1.962; 95% CI, 1.582–2.433); residency at medium-sized cities (OR, 1.295; 95% CI, 1.094–1.532); high-school graduation (OR, 1.440; 95% CI, 1.210–1.713); married status (OR, 2.281; 95% CI, 1.946–2.674); use of employment-based national health insurance (OR, 1.820; 95% CI, 1.261–2.626); use of private insurance (OR, 2.259; 95% CI, 1.970–2.589); no disability (OR, 1.428; 95% CI, 1.175–1.737); family history of CRC (OR, 2.027; 95% CI, 1.514–2.714); and history of colorectal neoplasm (OR, 1.216; 95% CI; 1.039–1.422).
Conclusion
The lack of regular participation in CRC screening programs in the Republic of Korea was found to be an issue that requires attention. Policies on CRC screening must place increased emphasis on strengthening educational and public relations initiatives.
6.Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
Jang Ho CHO ; Joon-Ho SHIM ; Sang Eun YOON ; Hee-Jin KIM ; Sun-Hee KIM ; Young Hyeh KO ; Seung-Tae LEE ; Kihyun KIM ; Won Seog KIM ; Seok Jin KIM
The Korean Journal of Internal Medicine 2021;36(3):668-678
Background/Aims:
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients.
Methods:
We retrospectively analyzed 47 patients diagnosed with WM between 2000 and 2018 to explore risk factors predicting poor prognosis using various clinical and laboratory parameters and risk models including the International Prognostic Staging System for WM (IPSS-WM).
Results:
Over a median follow-up duration of 80.4 months, 29 patients died. The main causes of death were disease progression, organ failure related to amyloidosis, and infection. The median overall survival (OS) was 55.1 months, and 14 patients, including three with amyloidosis, died within 2 years. Serum β2-microglobulin level higher than 4 mg/dL was significantly associated with poor OS. Accordingly, the IPSS-WM showed a significant association with poor prognosis compared with other risk models, and the low-risk group had better OS than intermediate- and high-risk groups. In the retrospective analysis using the results of targeted sequencing in two cases representing good and bad prognosis, different patterns of mutation profiles were observed, including mutations of MYD88, TP53, ARID1A, and JAK2 in a refractory case.
Conclusions
Serum β2-microglobulin could be a single biomarker strongly predictive of poor survival of WM patients, and the low-risk group of the IPSS-WM risk model including serum β2-microglobulin has better prognostic value than other risk models. Mutation analysis also might provide additional information to predict high-risk patients.
7.Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
Jang Ho CHO ; Joon-Ho SHIM ; Sang Eun YOON ; Hee-Jin KIM ; Sun-Hee KIM ; Young Hyeh KO ; Seung-Tae LEE ; Kihyun KIM ; Won Seog KIM ; Seok Jin KIM
The Korean Journal of Internal Medicine 2021;36(3):668-678
Background/Aims:
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder that usually follows an indolent clinical course. However, some patients show an aggressive clinical course leading to death. We explored the risk factors predicting poor prognosis in WM patients.
Methods:
We retrospectively analyzed 47 patients diagnosed with WM between 2000 and 2018 to explore risk factors predicting poor prognosis using various clinical and laboratory parameters and risk models including the International Prognostic Staging System for WM (IPSS-WM).
Results:
Over a median follow-up duration of 80.4 months, 29 patients died. The main causes of death were disease progression, organ failure related to amyloidosis, and infection. The median overall survival (OS) was 55.1 months, and 14 patients, including three with amyloidosis, died within 2 years. Serum β2-microglobulin level higher than 4 mg/dL was significantly associated with poor OS. Accordingly, the IPSS-WM showed a significant association with poor prognosis compared with other risk models, and the low-risk group had better OS than intermediate- and high-risk groups. In the retrospective analysis using the results of targeted sequencing in two cases representing good and bad prognosis, different patterns of mutation profiles were observed, including mutations of MYD88, TP53, ARID1A, and JAK2 in a refractory case.
Conclusions
Serum β2-microglobulin could be a single biomarker strongly predictive of poor survival of WM patients, and the low-risk group of the IPSS-WM risk model including serum β2-microglobulin has better prognostic value than other risk models. Mutation analysis also might provide additional information to predict high-risk patients.
8.First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism.
Heyjin KIM ; Kihyun KIM ; Sung Ran CHO ; Hee Jin KIM ; Sun Hee KIM
Annals of Laboratory Medicine 2019;39(1):96-98
No abstract available.
Hyperparathyroidism*
;
Multiple Myeloma*
;
Plasma Cells*
;
Plasma*
9.A Case of Extramedullary Plasmacytoma Presenting as a Large Jugular Foramen Tumor.
Jung Joo LEE ; Kihyun KIM ; Yang Sun CHO
Korean Journal of Otolaryngology - Head and Neck Surgery 2017;60(5):243-247
Extramedullary plasmacytoma is a non-epithelial neoplasm of plasma cell origin that does not accompany a systemic spread. Only a few cases of this disease developed in the temporal bone have been reported so far. This case report describes an unusual case of solitary extramedullary plasmacytoma of the temporal bone that mimicked a large jugular foramen tumor with hypoglossal canal involvement. The tumor was diagnosed by a biopsy from the external auditory canal at the outpatient clinic, and effectively controlled with primary radiotherapy. Based on our experience, when a jugular foramen tumor is suspected, such as in the case of extramedullary plasmacytoma, a biopsy for pathologic investigation should be considered whenever necessary in order to distinguish lesions that may not require nonsurgical treatment.
Ambulatory Care Facilities
;
Biopsy
;
Ear Canal
;
Plasma Cells
;
Plasmacytoma*
;
Radiotherapy
;
Temporal Bone
10.Gene Therapy for Bone Tissue Engineering.
Young Dong KIM ; Prasad POFALI ; Tae Eun PARK ; Bijay SINGH ; Kihyun CHO ; Sushila MAHARJAN ; Prajakta DANDEKAR ; Ratnesh JAIN ; Yun Jaie CHOI ; Rohidas AROTE ; Chong Su CHO
Tissue Engineering and Regenerative Medicine 2016;13(2):111-125
Gene therapy holds a great promise and has been extensively investigated to improve bone formation and regeneration therapies in bone tissue engineering. A variety of osteogenic genes can be delivered by combining different vectors (viral or non-viral), scaffolds and delivery methodologies. Ex vivo & in vivo gene enhanced tissue engineering approaches have led to successful osteogenic differentiation and bone formation. In this article, we review recent advances of gene therapy-based bone tissue engineering discussing strengths and weaknesses of various strategies as well as general overview of gene therapy.
Bone and Bones*
;
Bone Morphogenetic Proteins
;
Genetic Therapy*
;
Osteogenesis
;
Regeneration
;
Tissue Engineering

Result Analysis
Print
Save
E-mail